Nomination of Dr. Frank Mathias as Chairman of the Board

Jun 25, 2024

ArcticZymes Technologies Announces Nomination of Dr. Frank Mathias as Chairman of the Board

Tromsø, Norway – June 25, 2024 – ArcticZymes Technologies is pleased to announce the nomination of Dr. Frank Mathias as the new Chairman of the Board.

Dr. Mathias is the CEO at Oxford Biomedica, a leading pure-play CDMO within the cell and gene therapy industry. Dr. Mathias was previously the CEO of Rentschler Biopharma SE, which he successfully developed into a leading global, full-service CDMO. Prior to Rentschler, Dr. Mathias served as CEO of Medigene AG, a publicly listed immuno-oncology company. During his 30-year career, Dr. Mathias has held senior roles at leading global pharmaceutical companies, including Amgen Deutschland GmbH, Servier Deutschland GmbH, and Hoechst AG. In 2019, he was awarded the “EY Entrepreneur of the Year” title in Germany. Dr. Mathias is a pharmacist by training and completed his Doctorate in Pharmacy at Paris VI University.

“We are very pleased to nominate Frank Mathias as our new Chairman of the Board,” said Jon R. Sandberg, Chairman of the Nomination Committee. “Frank Mathias’ extensive experience and visionary leadership make him the ideal candidate to guide our company into its next phase of development, commercialization and growth.”

“I am honoured to join ArcticZymes at such a pivotal time,” said Dr. Frank Mathias. “The innovative enzyme solutions developed by ArcticZymes have made significant contributions to advancements in biomanufacturing, enhancing efficiency and quality across the industry. I look forward to contributing to the company’s continued success and collaborative growth.”

‍For more information, please contact:

ArcticZymes Technologies ASA
CEO, MIchael B. Akoh, Tel: +46 (0) 70 262 37 15
CFO, Børge Sørvoll, Tel: +47 95 29 01 87
ir@arcticzymes.com

‍

ArcticZymes Highlights Industry-Leading Success at ESGCT 2024

Oct 24, 2024

ArcticZymes Technologies ASA (OSE: AZT), a global leader in enzyme innovation for bioprocessing, is excited to unveil breakthrough developments presented at the prestigious European Society of Gene and Cell Therapy (ESGCT) 2024 conference

ArcticZymes Leverages Rising Interest in Salt-Active Nucleases with New Whitepaper on Advancing Viral Vector Manufacturing

Sep 17, 2024

ArcticZymes Leverages Rising Interest in Salt-Active Nucleases with New Whitepaper on Advancing Viral Vector Manufacturing

Research Paper About Novel RNA Restriction Enzyme Published in Journal: Nucleic Acids Research

Sep 16, 2024

ArcticZymes Technologies ASA Publishes Innovative Research on Novel RNA Restriction Enzyme, Paving the Way for Precision RNA Manipulation

ArcticZymes Technologies Q2 and 6M 2024 Results – Progress in partnership discussions and portfolio development

Aug 22, 2024

Tromsø, Norway, Aug 22, 2024 – ArcticZymes Technologies (OSE: AZT) reported revenues of NOK 27.5 million and an EBITDA of NOK 2.6 million for the second quarter of 2024.

Announcement of New Chairman and Board Members

Jun 27, 2024

Tromsø, Norway, June 27th, 2024—ArcticZymes Technologies (OSE: AZT) Announces Announces New Chairman and Board Members

Nomination of Dr. Frank Mathias as Chairman of the Board

Jun 25, 2024

Tromsø, Norway, June 25th, 2024—ArcticZymes Technologies (OSE: AZT) Announces Nomination of Dr. Frank Mathias as Chairman of the Board

Notice of Annual General Meeting 2024

Jun 5, 2024

The annual general meeting (“AGM”) in ArcticZymes Technologies ASA will be held on Wednesday, June 26th, 2024, at 15.00 CET.

ArcticZymes Technologies Changes to the Board of Directors

May 13, 2024

Tromsø, Norway, May 13th, 2024—ArcticZymes Technologies (OSE: AZT) announces Nominations for new Board members and the resignations of the Chairman and a Board member.

Presentation of Q1 2024 Results

May 8, 2024

Tromsø, Norway, May 8th, 2024 – ArcticZymes Technologies (OSE: AZT) reported sales of NOK 30.0 million and an EBITDA of NOK 2.3 million for the first quarter of 2024.

Joint Research with Austrian Centre of Industrial Biotechnology

Apr 9, 2024

Tromsø, Norway, April 9, 2024 - ArcticZymes Technologies ASA (OSE: AZT) and the Austrian Centre of Industrial Biotechnology (acib) enter a joint research project to uncover the benefits of salt active nucleases in the purification of bionanoparticles (BNP’s).

Research Paper on ArcticZymes R2D Ligase Published in the Biotechnology Journal

Mar 27, 2024

Tromsø, Norway, March 27, 2024 - ArcticZymes Technologies ASA (OSE: AZT) Research Paper on ArcticZymes R2D Ligase™ is published in the Biotechnology Journal

ArcticZymes Technologies ASA Q4 2023 Results & Presentation

Feb 1, 2024

Tromsø, Norway, February 1st, 2024 – ArcticZymes Technologies (OSE: AZT) reported sales of NOK 28.4 million and an EBITDA of NOK 2.0 million for the fourth quarter of 2023.

New Product Launch - SAN HQ GMP

Jan 30, 2024

Tromsø, Norway, January 30th, 2024 – ArcticZymes Technologies ASA (OSE:AZT) announces the launch of Salt Active Nuclease High Quality GMP Grade (SAN HQ GMP).

ArcticZymes Technologies launches T7 RNA Polymerase

Dec 21, 2023

Tromsø, Norway, December 21, 2023 – ArcticZymes Technologies ASA (OSE: AZT) announced the launch of its new product, T7 RNA Polymerase. The T7 RNA Polymerase, specifically designed for molecular research and diagnostics, caters to the specialized needs of our customers in the Molecular Tools segment.

ArcticZymes Technologies Announces Partnership with Biomatter

Dec 19, 2023

Tromsø, Norway, December 19, 2023 – ArcticZymes Technologies ASA (OSE: AZT) enters an agreement with Biomatter (Biomatter Designs UAB) to develop new enzyme-based products.

ArcticZymes launches new website - Improved product info & customer experience

Dec 1, 2023

Tromsø, Norway, December 1st, 2023 - ArcticZymes Technologies ASA (OSE:AZT) announces the launch of its innovative new website with enhanced user ...

Long-Term Incentive Plan – share option grant to primary insider

Nov 3, 2023

Tromsø, Norway, November 3rd, 2023 – ArcticZymes Technologies ASA (OSE:AZT) The Board of Directors in ArcticZymes Technologies ASA has decided to grant 200.000 share options...

ArcticZymes Technologies ASA Q3 2023 results & presentation

Nov 2, 2023

Tromsø, Norway, November 2nd, 2023 – ArcticZymes Technologies (OSE: AZT) reported sales of NOK 31.2 million and an EBITDA of NOK 7.3 million for the third quarter of 2023. Highlights from Q3 and 9 months 2023 ArcticZymes Technologies (AZT) had Q3 sales of NOK 31.2 million (Q3 2022: NOK 29.3 million) and sales for the first 9 months of NOK …

DMF for SAN HQ GMP accepted by the US FDA

Sep 21, 2023

Tromsø, Norway, September 21st, 2023 – ArcticZymes Technologies ASA (OSE:AZT) announces that Salt Active Nuclease High Quality GMP grade (SAN HQ GMP) has passed the DMF filing Type II with the US Food and Drug Administration (FDA) and has received the acknowledgement letter with the Master File number 29754 as a reference. This means that ArcticZymes can provide its customers …

ArcticZymes Technologies ASA Q2 and 6 months 2023 results

Aug 17, 2023

Tromsø, Norway, August 17th, 2023 – ArcticZymes Technologies (OSE: AZT) reported sales of NOK 28.2 million and an EBITDA of NOK 6.8 million for the second quarter of 2023. Highlights from Q2 and 6 months 2023 ArcticZymes Technologies (AZT) had Q2 sales of NOK 28.2 million (Q2 2022: NOK 30.4 million) and sales for the first 6 months of NOK …

ArcticZymes Technologies launches SAN HQ 2.0 ELISA Kit

ArcticZymes Technologies is pleased to announce the launch of our newest product, the SAN HQ 2.0 ELISA kit. This classic sandwich ELISA is designed for the detection and quantification of SAN HQ 2.0 enzyme in samples taken from the manufacturing stages of a complex biomanufacturing process such as the production of viral vectors. The SAN HQ 2.0 ELISA Kit is

ArcticZymes Technologies releases its first ESG report

Dec 30, 2022

Tromsø, Norway, 30st December 2022 – ArcticZymes Technologies ASA (OSE: AZT) releases its first comprehensive ESG report ArcticZymes Technologies has today released its first comprehnesive Environment, Social and Governane (ESG) report based on data for the year 2021. The report is prepared in accordance with the framework established by the Global Reporting Initiative (GRI) and the Sustainability Accounting Standards Board

ArcticZymes Technologies Q4, full year 2022 results and extended investor presentation

Feb 2, 2023

Tromsø, Norway, 2th February 2022 – ArcticZymes Technologies (OSE: AZT) reported sales of NOK 28.2 million (40.5) and an EBITDA of NOK 1.3 million (20.8) for the fourth quarter of 2022. Highlights from Q4 and the full year 2022 ArcticZymes Technologies (AZT) had Q4 sales of NOK 28.2 million a reduction of 30% (Q4 2021: NOK 40.5 million) and sales

ArcticZymes Technologies announces CEO resignation

Mar 22, 2023

Tromso, March 22nd 2023 – ArcticZymes Technologies ASA (OSE: AZT) announces that the Board of Directors has today accepted the voluntary resignation of Jethro Holter as Chief Executive Officer, due to personal reasons. The resignation will take effect on 30th September 2023 after the required 6 months notice period. “On behalf of the Board, I want to thank Jethro very

ArcticZymes Technologies launches ArcticZymes Proteinase HQ

Apr 18, 2023

Tromsø, Norway, April 18nd 2023 – ArcticZymes Technologies ASA (OSE:AZT) announces the launch of ArcticZymes Proteinase HQ to the B2B market. Following up on earlier press-releases (9th Dec 2022) ArcticZymes is pleased to launch the latest member in our Proteinase product portfolio: ArcticZymes Proteinase HQ. This product is the ‘bioprocessing grade’ version of our existing successful ArcticZymes Proteinase and will be

Q1 2023 Results and presentation

May 3, 2023

Tromsø, Norway, 03rd May 2023 – ArcticZymes Technologies (OSE: AZT) reported sales of NOK 31.2 million and an EBITDA of NOK 6.1 million for the first quarter of 2023. Highlights from Q1 2023 ArcticZymes Technologies (AZT) had Q1 sales of NOK 31.2 million (Q1 2022: NOK 49.2 million, NOK 35.2 million adjusted for Covid effects in Q1 2022) AZT had

Notice of Annual General Meeting

Aug 6, 2023

The annual general meeting (“AGM”) in ArcticZymes Technologies ASA will be held on Tuesday 06. June 2023 at 12.00 CET. The meeting will be held as a virtual meeting, with an option for shareholders to participate digitally. Please click HERE for the notice and appendicies Shareholders who wish to attend the AGM, in person, electronically or by proxy, are requested to

ArcticZymes Technologies has filed DMF for SAN HQ GMP

Jun 29, 2023

Tromsø, Norway, June 29th 2023 – ArcticZymes Technologies ASA (OSE:AZT) announces the filing of a Drug Master File (DMF) to the US Food and Drug Administration (FDA) for Salt Active Nuclease High Quality GMP Grade (SAN HQ GMP). ArcticZymes is pleased to announce the filing of a DMF (Type II) for SAN HQ GMP with the US FDA’s Center for

ArcticZymes Technologies launches AZtaq™ DNA Polymerase

Aug 10, 2023

Tromsø, Norway, August 10th, 2023 – ArcticZymes Technologies ASA (OSE: AZT) launches AZtaq™ DNA Polymerase. ArcticZymes Technologies (AZT) today announces the launch of its new product, AZtaq™ DNA Polymerase. AZtaq™ is a high-quality thermostable DNA polymerase suitable for use in polymerase chain reaction (PCR) applications. Launching the AZtaq™ is a natural expansion of the Company’s molecular tools portfolio. Being an